Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Aethon Therapeutics.

    Client Virtual Booth

    AETHON THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Aethon Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    New York
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aethontx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aethon-therapeutics/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs

    Details:

    Under the collaboration, Aethon will use its HapImmune™ platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines' RAS(ON) inhibitors.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Revolution Medicines

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration April 04, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells

    Details:

    Aethon’s proprietary HapImmune™ platform is a mechanism to increase the antigenicity of any cancer-specific protein that can be targeted with any covalent drug and presented by the major histocompatibility complex (MHC), an essential component of the adaptive immune system.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Apple Tree Partners

    Deal Size: $30.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing January 09, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search